InMed advances $290M reverse merger with migraine biotech Mentari
What's the deal? InMed PharmaceuticalsDealroom has a profile for this one. Try Dealroom → has amended its all-stock merger agreement with Mentari TherapeuticsDealroom has a profile for this one. Try Dealroom → and filed a Form S-4 registration statement with the US Securities and Exchange Commission. The move advances a reverse merger that will turn Nasdaq-listed InMed into a public vehicle for Mentari, a privately held biotech developing migraine prevention therapies.
Why now? InMed filed the S-4 on July 2, 2026, and announced the amendment on July 6. The filing is procedural but necessary: once the SEC declares it effective, InMed can set a shareholder vote and mail the definitive proxy statement.
What does the amendment change? It clarifies the sequencing of the transactions, the impact of pre-closing financing on the exchange ratio, and the intended tax treatment of the merger. Both companies' boards have approved the deal, which is expected to close in the fourth quarter of 2026, subject to shareholder approvals and other conditions.
What are the companies building? Mentari is developing therapies to prevent migraine, a condition it says affects more than 1 billion people globally. Its lead programs target PACAP, a validated target independent from CGRP, and include MT-001, an anti-PACAP monoclonal antibody for subcutaneous dosing. InMed, by contrast, focuses on small-molecule drug candidates targeting CB1/CB2 receptors across Alzheimer's, ocular, and dermatological programs.
What are the terms? The combined company will be renamed Mentari Therapeutics. Pre-merger InMed shareholders are set to hold roughly 1.5% of the entity, underscoring that this is effectively a backdoor listing. The deal is paired with an oversubscribed US$290m private placement, led by specialist investors including FairmountDealroom has a profile for this one. Try Dealroom →, intended to fund operations and Phase 1 data readouts through 2028.
What could go wrong? The S-4 has not yet become effective, and its contents remain subject to change. Closing still depends on approval from both sets of shareholders and other customary conditions.
The signal: The filing marks another well-funded neurology entrant using a reverse merger to reach public markets. With an implied combined market cap near US$421m and strong investor appetite for next-generation migraine prevention, the deal stands apart from routine micro-cap combinations.
Read more: Finanznachrichten
Image credit: National Institutes of Health (NIH)
